Prof. Fröhling

Prof. Dr. Stefan Fröhling

Managing Director NCT Heidelberg
Head of Division:
Translational Medical Oncology, DKFZ

Phone: +49 6221 56-6990/-35212
Fax: +49 6221 56-6967

Since February 2020, Professor Stefan Fröhling has been Managing Director of NCT Heidelberg. In addition, he heads the division of Translational Medical Oncology at DKFZ. Stefan Fröhling’s research aims at providing as many patients as possible with individually tailored cancer treatments. As part of the Precision Oncology Program, much of his work is centered on the development of tools for the comprehensive molecular and functional characterization of individual tumors, and the conception of clinical studies examining the efficacy of modern, molecularly targeted treatment approaches. In addition to his research in the precision oncology field, Stefan Fröhling particularly focuses on the biology of bone and soft-tissue sarcomas as well as acute forms of leukemia.

Since February 2020
Managing Director, NCT Heidelberg

Since Januar 2019
Head of the Division Translational Medical Oncology, German Cancer Research Center

Since April 2018
Acting Managing Director, NCT Heidelberg

Attending Physician, Department of Translational Oncology, NCT/German Cancer Research Center and Department of Medical Oncology, NCT/Heidelberg University Hospital

Attending Physician, Research Group Leader, Department of Hematology, Oncology, Rheumatology, Infectious Diseases, Ulm University Hospital

Fellow, Research Group Leader, Department of Hematology, Oncology, Rheumatology, Infectious Diseases, Ulm University Hospital

Postdoctoral Scientist, Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School

Fellow in Internal Medicine, Hematology, Oncology, Rheumatology, Infectious Diseases, Ulm University Hospital

Resident in Internal Medicine, Hematology, Oncology, Rheumatology, Heidelberg University Hospital

Associate Professor (“Außerplanmäßige Professur”), Ulm University


Assistant Professor (“Habilitation”), Ulm University


Doctor of Medicine (“Promotion”), Heidelberg University

Heidelberg University Medical School, Germany

Marburg University Medical School, Germany

Since 2017
Sarcoma Alliance for Research through Collaboration (SARC)

Since 2014
German Interdisciplinary Sarcoma Group (GISG)

Since 2009
American Association for Cancer Research (AACR)

Since 2008
European Hematology Association (EHA)

Since 2001
American Society of Hematology (ASH)

Uncommon Collaboration Award, Chordoma Foundation

Young Investigator Fellowship, European Hematology Association-José Carreras Leukämie-Stiftung

Research Fellowship, German Research Foundation

Leukemia Research Award, Franziska Kolb Foundation

Andrea Fries

Phone: +49 6221 56-6762
Fax: +49 6221 56-6967

Dr. Laura Pelz

Scientific coordinator of the local coordination office of the NCT
Phone: +49 6221 56-38229
Fax: +49 6221 56-6967

Dr. Annika Baude

Scientific coordinator
(on parental leave)
Phone: +49 6221 56-38229
Fax: +49 6221 56-6967

Petra Oberrauch

NCT Network Coordinator
Phone: +49 6221 56-6794
Fax: +49 6221 56-6967

Dr. Monika Huber

NCT Network Coordinator
Phone: +49 6221 56-6794
Fax: +49 6221 56-6967

  1. Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Di Marcantonio D, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S,* Scholl C.* RET-mediated autophagy suppression as targetable codependence in acute myeloid leukemia. Leukemia. Accepted for publication.
  2. Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig C, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun 9:144, 2018.
  3. Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W,* Glimm H,* Fröhling S.* Mutant KIT as imatinibsensitive target in metastatic sinonasal carcinoma. Ann Oncol 8:142-148, 2017.
  4. Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S. Targeting FGFR1 for treatment of soft-tissue sarcoma. Clin Cancer Res 23:962-973, 2017.
  5. Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H,* Brummer T,* Fröhling S.* Cooperation of BRAF F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia 30:937-946, 2016.

Prof. Dr. Stefan Fröhling